Ocular Therapeutix (OCUL) News Today → Wall Street Legend Warns: 'A Strange Day Is Coming to America' (From Chaikin Analytics) (Ad) Free OCUL Stock Alerts $5.93 +0.13 (+2.24%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 7:52 PM | marketbeat.comSanjay Nayak Sells 2,274 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) StockOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Sanjay Nayak sold 2,274 shares of the stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $5.84, for a total transaction of $13,280.16. Following the transaction, the insider now owns 178,026 shares of the company's stock, valued at approximately $1,039,671.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.May 28 at 6:47 AM | marketbeat.com4,500,159 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Bought by Franklin Resources Inc.Franklin Resources Inc. acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,500,159 shares of the biopharmaceuticaMay 15, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Trading 7.8% Higher Ocular Therapeutix (NASDAQ:OCUL) Trading 7.8% HigherMay 15, 2024 | finance.yahoo.comOcular Therapeutix Inc Reports First Quarter 2024 EarningsMay 8, 2024 | markets.businessinsider.comMaintaining Buy Rating on Ocular Therapeutix: Financial Growth and Advancements in Clinical Trials Signal Strong ProspectsMay 8, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) PT Lowered to $14.00 at HC WainwrightHC Wainwright dropped their target price on Ocular Therapeutix from $16.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday.May 7, 2024 | washingtonpost.comOcular Therapeutix: Q1 Earnings SnapshotMay 7, 2024 | investorplace.comOCUL Stock Earnings: Ocular Therapeutix Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | globenewswire.comOcular Therapeutix™ Reports First Quarter 2024 ResultsMay 7, 2024 | finanznachrichten.deOcular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2024 | markets.businessinsider.comOcular Therapeutix is about to announce its earnings — here's what to expectMay 6, 2024 | globenewswire.comOcular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Down to $6.17Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down to $6.17May 6, 2024 | msn.comEyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goalMay 5, 2024 | stockhouse.comOcular Therapeutix(TM) To Present at Two Ophthalmology Meetings, May 4-9, 2024May 3, 2024 | globenewswire.comOcular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024May 2, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Trading 10% Higher Ocular Therapeutix (NASDAQ:OCUL) Trading Up 10%May 1, 2024 | globenewswire.comOcular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024April 26, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Up 10.7%Ocular Therapeutix (NASDAQ:OCUL) Shares Up 10.7%April 24, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Down 5% Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 5%April 24, 2024 | fool.com2 Small-Cap Growth Stocks With Room To RunApril 22, 2024 | markets.businessinsider.comOptimistic Buy Rating for Ocular Therapeutix Amid Early-Stage NPDR Study and Wet AMD PotentialApril 19, 2024 | msn.comBaird sees weakness in Ocular shares as "overdone"April 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)April 19, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Sees Strong Trading VolumeOcular Therapeutix (NASDAQ:OCUL) Sees Large Volume IncreaseApril 19, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of Ocular Therapeutix in a report on Friday.April 18, 2024 | marketwatch.comOcular Therapeutix Shares Dive on Axpaxli Trial ResultsApril 18, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Stock Price Down 9.2%Ocular Therapeutix (NASDAQ:OCUL) Shares Down 9.2%April 18, 2024 | markets.businessinsider.comOcular Therapeutix Reports Positive Phase 1 Data For Axpaxli In NPDRApril 18, 2024 | seekingalpha.comOcular marks early-stage trial win for diabetic retinopathy candidateApril 18, 2024 | globenewswire.comOcular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic RetinopathyApril 17, 2024 | theglobeandmail.comAge-related Vision Dysfunction Market Size in the 7MM is anticipated to increase by 2032, estimates DelveInsightApril 17, 2024 | uk.investing.comOcular Therapeutix appoints new CEO amid leadership shiftApril 17, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Up to $7.79Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up to $7.79April 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Ocular Therapeutix (OCUL) and Elevance Health (ELV)April 16, 2024 | markets.businessinsider.comThe Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 ExpertsApril 16, 2024 | marketbeat.comJMP Securities Reaffirms Market Outperform Rating for Ocular Therapeutix (NASDAQ:OCUL)JMP Securities reaffirmed a "market outperform" rating and issued a $24.00 target price on shares of Ocular Therapeutix in a research report on Tuesday.April 16, 2024 | stockhouse.comOcular Therapeutix(TM) Strengthens Clinical Team with Appointment of Key Retinal LeadersApril 16, 2024 | finance.yahoo.comOcular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal LeadersApril 15, 2024 | marketbeat.comShort Interest in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Increases By 28.9%Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 11,810,000 shares, a growth of 28.9% from the March 15th total of 9,160,000 shares. Based on an average daily volume of 2,050,000 shares, the days-to-cover ratio is presently 5.8 days.April 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 15, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Down to $7.99Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down to $7.99April 15, 2024 | marketwatch.comOcular Therapeutix CEO Mattessich Steps Down, Executive Chairman Fills RoleApril 15, 2024 | markets.businessinsider.comOcular Therapeutix CEO Mattessich To Step Down, Dugel To SucceedApril 15, 2024 | globenewswire.comOcular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEOApril 13, 2024 | msn.comRemedies Recommended For Ocular RosaceaApril 11, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Up 3.9%Ocular Therapeutix (NASDAQ:OCUL) Trading Up 3.9%April 9, 2024 | globenewswire.comOcular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of BiometricsApril 8, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Up to $8.44Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up to $8.44April 8, 2024 | markets.businessinsider.comBuy Rating Affirmed: Paxtrava’s Promising Efficacy and Safety Profile in Glaucoma Treatment Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address Wall Street Legend Warns: "A Strange Day Is Coming to America" (Ad)Get Your Cash Out of U.S. Banks Immediately Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more. OCUL Media Mentions By Week OCUL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCUL News Sentiment▼1.890.89▲Average Medical News Sentiment OCUL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCUL Articles This Week▼33▲OCUL Articles Average Week Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INVA News Today PLRX News Today ARQT News Today PHAT News Today KNSA News Today TBPH News Today SUPN News Today KPTI News Today AXSM News Today MRUS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCUL) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsBitcoin’s Biggest Year YetParadigm PressThe #1 Crypto for AIWeiss RatingsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesElon’s New Device is About to Shock the WorldInvestorPlaceHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
